Cancer Medicine (Aug 2019)
Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study
- Antonio Tejera‐Vaquerizo,
- Simone Ribero,
- Susana Puig,
- Aram Boada,
- Sabela Paradela,
- David Moreno‐Ramírez,
- Javier Cañueto,
- Blanca deUnamuno,
- Ana Brinca,
- Miguel A. Descalzo‐Gallego,
- Simona Osella‐Abate,
- Paola Cassoni,
- Cristina Carrera,
- Sergi Vidal‐Sicart,
- Antoni Bennássar,
- Ramón Rull,
- Llucìa Alos,
- Celia Requena,
- Isidro Bolumar,
- Víctor Traves,
- Ángel Pla,
- A. Fernández‐Orland,
- Ane Jaka,
- María T. Fernández‐Figueres,
- Josep M. Hilari,
- Pol Giménez‐Xavier,
- Ricardo Vieira,
- Rafael Botella‐Estrada,
- Concepción Román‐Curto,
- Lara Ferrándiz,
- Nicolás Iglesias‐Pena,
- Carlos Ferrándiz,
- Josep Malvehy,
- Pietro Quaglino,
- Eduardo Nagore,
- on behalf of SENTIMEL group
Affiliations
- Antonio Tejera‐Vaquerizo
- Dermatology Department Instituto Dermatológico GlobalDerm Palma del Río, Córdoba Spain
- Simone Ribero
- Medical Sciences Department, Section of Dermatology University of Turin Turin Italy
- Susana Puig
- Melanoma Unit, Dermatology Department, Hospital Clinic Universitat de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- Aram Boada
- Departamento de Dermatología Hospital Universitari Germans Trial i Pujol Badalona Spain
- Sabela Paradela
- Departamento de Dermatología Hospital Universitario de la Coruña La Coruña Spain
- David Moreno‐Ramírez
- Melanoma Unit, Medical‐&‐Surgical Dermatology Department Hospital Universitario Virgen Macarena Sevilla Spain
- Javier Cañueto
- Servicio de Dermatología Complejo Asistencial Universitario de Salamanca Salamanca Spain
- Blanca deUnamuno
- Departamento de Dermatología Hospital Universitario La Fe Valencia Spain
- Ana Brinca
- Department of Dermatology University Hospital of Coimbra Coimbra Portugal
- Miguel A. Descalzo‐Gallego
- Unidad de Investigación Academia Española de Dermatología Fundación Piel Sana Madrid Spain
- Simona Osella‐Abate
- Medical Sciences Department, Section of Surgical Pathology University of Turin Turin Italy
- Paola Cassoni
- Medical Sciences Department, Section of Surgical Pathology University of Turin Turin Italy
- Cristina Carrera
- Melanoma Unit, Dermatology Department, Hospital Clinic Universitat de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- Sergi Vidal‐Sicart
- Nuclear Medicine Department Hospital Clinic Barcelona, Universitat de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- Antoni Bennássar
- Melanoma Unit, Dermatology Department, Hospital Clinic Universitat de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- Ramón Rull
- Surgery Department Hospital Clinic Barcelona Spain
- Llucìa Alos
- Pathology Department, Hospital Clinic Universidad de Barcelona Barcelona Spain
- Celia Requena
- Dermatology Department Instituto Valenciano de Oncología Valencia Spain
- Isidro Bolumar
- Surgery Department Instituto Valenciano de Oncología Valencia Spain
- Víctor Traves
- Pathology Department Instituto Valenciano de Oncología Valencia Spain
- Ángel Pla
- Otorhinolaringology Department Instituto Valenciano de Oncología Valencia Spain
- A. Fernández‐Orland
- Melanoma Unit, Medical‐&‐Surgical Dermatology Department Hospital Universitario Virgen Macarena Sevilla Spain
- Ane Jaka
- Departamento de Dermatología Hospital Universitari Germans Trial i Pujol Badalona Spain
- María T. Fernández‐Figueres
- Pathology Department Hospital Universitari Germans Trial i Pujol Badalona Spain
- Josep M. Hilari
- Departamento de Dermatología Hospital Universitari Germans Trial i Pujol Badalona Spain
- Pol Giménez‐Xavier
- Melanoma Unit, Dermatology Department, Hospital Clinic Universitat de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- Ricardo Vieira
- Department of Dermatology University Hospital of Coimbra Coimbra Portugal
- Rafael Botella‐Estrada
- Departamento de Dermatología Hospital Universitario La Fe Valencia Spain
- Concepción Román‐Curto
- Servicio de Dermatología Complejo Asistencial Universitario de Salamanca Salamanca Spain
- Lara Ferrándiz
- Melanoma Unit, Medical‐&‐Surgical Dermatology Department Hospital Universitario Virgen Macarena Sevilla Spain
- Nicolás Iglesias‐Pena
- Departamento de Dermatología Hospital Universitario de la Coruña La Coruña Spain
- Carlos Ferrándiz
- Departamento de Dermatología Hospital Universitari Germans Trial i Pujol Badalona Spain
- Josep Malvehy
- Melanoma Unit, Dermatology Department, Hospital Clinic Universitat de Barcelona, Institut d'investigacions biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- Pietro Quaglino
- Medical Sciences Department, Section of Dermatology University of Turin Turin Italy
- Eduardo Nagore
- Dermatology Department Instituto Valenciano de Oncología Valencia Spain
- on behalf of SENTIMEL group
- DOI
- https://doi.org/10.1002/cam4.2358
- Journal volume & issue
-
Vol. 8,
no. 9
pp. 4235 – 4244
Abstract
Abstract Mitotic rate is no longer considered a staging criterion for thin melanoma in the 8th edition of the American Joint Committee on Cancer Staging Manual. The aim of this observational study was to identify prognostic factors for thin melanoma and predictors and prognostic significance of sentinel lymph node (SLN) involvement in a large multicenter cohort of patients with melanoma from nine tertiary care hospitals. A total of 4249 consecutive patients with thin melanoma diagnosed from January 1, 1998 to December 31, 2016 were included. The main outcomes were disease‐free interval and melanoma‐specific survival for the overall population and predictors of SLN metastasis (n = 1083). Associations between survival and SLN status and different clinical and pathologic variables (sex, age, tumor location, mitosis, ulceration, regression, lymphovascular invasion, histologic subtype, Clark level, and Breslow thickness) were analyzed by Cox proportional hazards regression and logistic regression. SLN status was the most important prognostic factor for melanoma‐specific survival (hazard ratio, 13.8; 95% CI, 6.1‐31.2; P 2 mitoses/mm2 was the only factor associated with a positive SLN biopsy (odds ratio, 2.9; 95% CI, 1.22‐7; P = 0.01. SLN status is the most important prognostic factor in thin melanoma. A high mitotic rate is associated with metastatic SLN involvement. SLN biopsy should be discussed and recommended in patients with thin melanoma and a high mitotic rate.
Keywords
- age factors
- Cox proportional hazards regression analysis
- melanoma
- mitotic index
- multiple imputation
- neoplasia staging